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The establishment of robust HCV cell culture systems and charac-
terization of the viral life cycle provided the molecular basis for
highly innovative, successful years in HCV drug development.
With the identiﬁcation of direct-acting antiviral agents (DAAs),
such as NS3/4A protease inhibitors, NS5A replication complex
inhibitors, nucleotide and non-nucleoside polymerase inhibitors,
as well as host cell targeting agents, novel therapeutic strategies
were established and competitively entered clinical testing. The
ﬁrst-in-class NS3/4A protease inhibitors telaprevir and bocepre-
vir, approved in 2011, were recently outpaced by the pan-geno-
typic nucleotide polymerase inhibitor sofosbuvir that in
combination with pegylated interferon and ribavirin, further
shortens therapy durations and also offers the ﬁrst interferon-
free HCV treatment option. In the challenging race towards the
goal of interferon-free HCV therapies, however, several oral
DAA regimens without nucleotide polymerase inhibitors that
combine a NS3/4A protease inhibitor, a NS5A inhibitor and/or a
non-nucleoside polymerase inhibitor yielded competitive results.
Second generation NS3/4A protease and NS5A inhibitors promise
an improved genotypic coverage and a high resistance barrier.
Results of novel DAA combination therapies without the back-
bone of a nucleotide polymerase inhibitor, as well as treatment
strategies involving host targeting agents are reviewed herein.
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Hepatitis C virus (HCV) infection is a major public health burden
with an estimated 185 million anti-HCV positive individuals
worldwide [1]. The risk for the development of HCV-related
complications such as liver cirrhosis and the rising incidence of
HCV-related hepatocellular carcinoma have encouraged the
development of novel, effective therapeutic strategies [2].
Particularly, unravelling of the HCV life cycle, enabled by the
availability of robust HCV cell culture systems, afforded the
opportunity to identify direct-acting antiviral drug targets and
respective antiviral agents [3–5]. In fact, numerous direct-acting
antiviral agents (DAAs) belonging to different drug classes, such
as NS3/4A protease inhibitors, NS5A replication complex inhibi-
tors, nucleos(t)ide and non-nucleoside polymerase inhibitors
have been developed (reviewed in [6]; Table 1A). Also, host-tar-
geting agents (HTAs) that act against cellular pathways involved
in viral entry or replication, could be identiﬁed [7] (Table 1B). So
far, clinical trials investigating the different drug classes and their
combinations with or without pegylated interferon (PegIFN) and/
or ribavirin (RBV) yielded highly promising sustained virologic
response (SVR) rates [6]. The proof that successful clearance of
HCV is possible with an all-oral DAA combination further stimu-
lated clinical trials, investigating novel, interferon-free DAA com-
bination therapies [8]. About two years after the NS3/4A protease
inhibitors telaprevir and boceprevir, used in combination with
PegIFN and RBV, became available, the ﬁrst nucleotide polymer-
ase inhibitor sofosbuvir was approved [9–11]. Sofosbuvir offers
the ﬁrst interferon-free therapeutic option (particularly for HCV
genotypes 2 and 3) and, in combination with PegIFN and RBV,
further shortens the therapy duration in HCV genotype 1 (and
3, 4, 5, 6) infected patients [12–14].
Nucleotide polymerase inhibitors have a high barrier to resis-
tance and confer a potent, pan-genotypic activity. Combination of
sofosbuvir with other DAAs, such as NS3/4A protease inhibitors
and NS5A inhibitors further improves SVR rates even in difﬁcult
to cure patient populations [15–20].
Interferon-free regimens without the backbone of a nucleosi-
dic polymerase inhibitor depend on combinations of two or more
DAAs with or without RBV, which is explained by a low barrier to
resistance of ﬁrst generation NS3/4A protease-, NS5A-, and non-
nucleoside polymerase inhibitors. First generation NS3/4A prote-
ase inhibitors and non-nucleoside polymerase inhibitors have
limited genotypic coverage (predominantly HCV genotype 1).14 vol. 61 j S98–S107
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Second generation NS3/4A protease inhibitors such as MK-5172,
ABT-493, promise an improved genotypic coverage and a higher
resistance barrier [21,22]. First and second generation NS5A
inhibitors differ less in their genotypic coverage, but the barrier
to resistance seems to be enhanced in second generation com-
pounds (i.e., MK-8742, GS-5816, GSK2336805, ABT-530) [23–26].
This review provides an overview over recent IFN-free DAA
combination trials without nucleoside/nucleotide analogue poly-
merase inhibitors.
Key Points
• DAA combination trials, particularly those involving 
the combination of a NS3/4A protease inhibitor and a 
NS5A inhibitor, or triple DAA combination therapies, 
additionally including a non-nucleoside polymerase 
inhibitor, report excellent virologic response rates in 
HCV genotype 1 therapy naïve and experienced 
patients, including patients with liver cirrhosis
• Ongoing efforts in HCV drug development include the 
investigation of second generation NS3/4A protease 
inhibitors and NS5A replication complex inhibitors that 
promise an improved genotypic coverage and higher 
resistance barrier
• The future role of host targeting agents needs to be 
definedInterferon-free, all-oral DAA combination trials without
nucleotide polymerase inhibitors
Combination of a NS3/4A protease inhibitor, a NS5A inhibitor ± RBV
All-oral, interferon-free DAA trials, investigating the combination
of a NS3/4A protease inhibitor and a NS5A inhibitor (with or with-
out RBV), yielded favourable results (summarized in Table 2).
ABT-450/r and ombitasvir (ABT-267) ± RBV
Combination of the ritonavir-boosted NS3/4A protease inhibitor
ABT-450/r and the NS5A inhibitor ombitasvir (formerly ABT-
267) was ﬁrst investigated in the AVIATOR study [27]. This phase
2b open-label trial enrolled non-cirrhotic HCV genotype (GT)
1-infected patients who were either treatment-naïve or null-
responders to prior therapy with PegIFN and RBV. Patients were
randomly assigned to one of fourteen treatment arms where they
received different doses of ABT450/r (100/100 mg, 150/100 mg, or
200/100 mg QD), in combination with ombitasvir (25 mg QD) or
the non-nucleoside polymerase inhibitor dasabuvir (formerly
ABT-333, 400 mg BID), with or without RBV. Therapy durations
were 8, 12 or 24 weeks. SVR rates in treatment-naïve patients
(n = 79) and prior null-responders (n = 45) who received ABT-
450/r, ombitasvir, and RBV for 12 weekswere 89% for both groups.
Results for other treatment arms (combinations of ABT450/r, das-
abuvir and RBV, or triple DAA combinations) are reviewed below.
Substudy 1 of the phase 2 PEARL-I trial investigated the efﬁ-
cacy of ABT450/r and ombitasvir (ABT-267), with or without
RBV, for 12 weeks in non-cirrhotic, treatment-naïve or experi-
enced patients with HCV GT1b or GT4 infection [28,29]. SVR12
rates were 95.2% and 90.0% in HCV GT1b-infected treatment-Journal of Hepatology 201naïve (n = 42) and prior null-responders (n = 40), respectively,
treated with a RBV-free combination of ABT-450/r (150/100 mg
QD) and ombitasvir (25 mg QD) for 12 weeks [28]. Also, all of
the 42 treatment-naïve HCV GT4-infected patients randomized
to the RBV-containing DAA regimen and 90.9% of the patients
treated with ABT-450/r and ombitasvir alone (n = 44) had a SVR
[29]. SVR12 results for treatment-experienced HCV GT4 patients
(n = 49) are not yet available.
Substudy 2 of the PEARL-1 trial investigates the efﬁcacy of
ABT-450/r and ombitasvir for 24 weeks in therapy naïve and
experienced HCV GT1b patients with liver cirrhosis. Results are
not yet available.
An ongoing open-label, phase 2 pilot study investigates the
combination of ABT-450/r and the next-generation NS5A inhibi-
tor ABT-530, with and without RBV for 12 weeks in therapy
naïve, HCV GT3-infected patients without cirrhosis [30].
Sovaprevir and ACH-3102 + RBV
The all-oral combination of sovaprevir, a next-generation NS3/4A
protease inhibitor (200 mg or 400 mg QD, n = 10 patients in each
group) and ACH-3102 (150/50 mg), a second generation NS5A
inhibitor and RBV was investigated in a placebo controlled,
open-label phase 2 study [31]. 100% of HCV GT1b patients
(n = 4 in each verum arm) achieved a SVR12. Suboptimal SVR
rates, however, were reported for HCV GT1a-infected patients
who experienced viral breakthrough (after week 2) or relapse.
In all of the treatment failures, NS3/4A resistance mutations were
detected at position 155. Also, most of the GT1a patients had 2 or
more resistance associated variants in the NS5A protein. Sovapre-
vir was placed on clinical hold after liver enzyme elevation was
reported from a phase 1 drug-drug interaction study, but clinical
development was recently resumed [32].
Asunaprevir and daclatasvir
A small exploratory phase 2a study investigated the interferon-
free all oral combination of the NS3/4A protease inhibitor asuna-
previr (ASV, 600 mg BID) and the ﬁrst-in class, once-daily NS5A
inhibitor daclatasvir (DCV, 60 mg QD) for 24 weeks in eleven
HCV genotype 1 null-responders to previous therapy with
PegIFN and RBV [8]. A sustained virologic response was achieved
in 2/2 HCV genotype 1b-infected patients but in only 2/9 (22.2%)
HCV genotype 1a-infected patients, due to high breakthrough
rates.
The efﬁcacy of this dual, RBV-free DAA regimen was further
investigated in several phase 2 studies, conducted in Japan and
the U.S. (summarized in Table 3) [33,34]. In the U.S. study
(NCT01012895), SVR24 rates in non-cirrhotic HCV genotype 1b
null-responders treated with asunaprevir 200 mg BID (group
A1, n = 18) or asunaprevir 200 mg QD and daclatasvir (60 mg
QD) (group A2, n = 20) for 24 weeks were 83% and 60% respec-
tively [34]. Most of the HCV GT1a-infected patients, treated with
asunaprevir 200 mg BID and daclatasvir 60 mg QD and RBV
(group B3, n = 22), experienced viral breakthrough.
Results of the asunaprevir/daclatasvir phase 3 program that
investigated the 24 week dual combination of asunaprevir
(100 mg BID) and daclatasvir (60 mg QD), restricted to HCV
genotype 1b-infected patients with and without cirrhosis, were
reported recently [35,36]. In the Japanese phase 3 trial, SVR rates
were 87.4% in interferon ineligible/intolerant patients (n = 135)4 vol. 61 j S98–S107 S99
Table 1. Overview over selected direct-acting antiviral agents (DAAs) and selected host-targeting agents for HCV therapy. (A) Overview over selected direct-acting
antiviral agents (DAAs), not including nucleos(t)ide analogues. (B) Overview over selected host-targeting agents for HCV therapy.
Direct-acting antiviral agents (DAAs) Company Clinical development 
NS3/4A protease inhibitors 
Linear   
Boceprevir (BOC) Merck Approved
Telaprevir (TPV) Vertex/Janssen Approved
ABT-450/r* AbbVie Phase 3
ABT-493 AbbVie Phase 2
Faldaprevir (BI 201335) Boehringer-Ingelheim Discontinued after completion of phase 3
Asunaprevir (ASV, BMS-650032) Bristol-Myers Squibb Phase 3  
Vedroprevir (GS-9451) Gilead Phase 2  
Narlaprevir (SCH 900518) Merck Phase 2
Vaniprevir (MK-7009) Merck Phase 3
Sovaprevir (ACH-1625) Achillion Phase 2 
Macrocyclic
Simeprevir (TMC435) Janssen Approved
MK-5172 Merck Phase 3
Danoprevir (DNV/r, RG-7227)* Roche Phase 3
ACH-2684 Achillion Phase 2
GS-9256 Gilead Discontinued
BZF-961 Novartis Phase 1
NS5A inhibitors
Daclatasvir (DCV, BMS-790052) Bristol-Myers-Squibb Approved
Ombitasvir (ABT-267) AbbVie Phase 3
ABT-530 AbbVie Phase 2
ACH-3102 Achillion Phase 2
Ledipasvir  (LDV, GS-5885)** Gilead Phase 3
GS-5816** Gilead Phase 2
GSK2336805 GlaxoSmithKline Phase 2
Samatasvir (IDX719) Idenix Pharmaceuticals Phase 2
MK-8742 Merck Phase 3
EDP239 Novartis Phase 1
PPI-461 Presidio Phase 1
PPI-668 Presidio Phase 2
Non-nucleoside polymerase inhibitors 
Thumb I
Deleobuvir (BI 207127) Boehringer-Ingelheim Discontinued after completion of phase 3
BMS-791325 Bristol-Myers-Squibb Phase 3
TMC647055 Medivir/Janssen Phase 2
Thumb II
GS-9669 Gilead Phase 2
Lomibuvir (VX-222 ) Vertex Phase 2
Palm I
ABT-072 AbbVie Discontinued 
Dasabuvir (ABT-333) AbbVie Phase 3
Setrobuvir (ANA-598,  RO5466731) Roche Discontinued
Palm II
Tegobuvir (GS-9190) Gilead Discontinued
A
(Continued on next page)
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Table 1 (continued).
B
Host targeting agent (HTAs) Company Clinical development 
Cyclophilin A inhibitors
Alisporivir Novartis Phase 2
SCY-635 Scynexis Phase 2
MicroRNA-122
Miravirsen Santaris Phase 2
⁄/r, Ritonavir-boosted.
⁄⁄, Fixed-dose combinations of sofosbuvir/ledipasvir and sofosbuvir/GS-5816.
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JOURNAL OF HEPATOLOGYand 80.5% in prior non-responders (null, partial, n = 87) to
therapy with PegIFN and RBV [35]. SVR rates of the placebo-
controlled ‘‘HALLMARK-DUAL’’ were reported with 90% in
treatment-naïve, 82% in ineligible/intolerant patients, and 82%
in non-responder patients [36]. In both trials, treatment
responses were independent of the IL28B genotype (IL28B-CC
vs. non-CC), and prior treatment experience. Also, response rates
were similar in non-cirrhotic and cirrhotic patients (90.9% vs. 84%
in the Japanese study and 84% and 85% in the ‘‘HALLMARK-DUAL’’
study). Overall, the dual DAA combination was well tolerated
with a manageable adverse event (AE) proﬁle and low number
of treatment discontinuations. Common adverse events included
fatigue, nausea, diarrhoea, headache and asthenia.T
re
aSimeprevir and daclatasvir ± RBV
The LEAQUE-1 study, a randomized, open-label, phase 2 study
investigated the oral combination of the NS3/4A protease inhibi-
tor simeprevir (150 mg QD) and a lower dose of daclatasvir
(30 mg) in HCV genotype 1b-infected, treatment-naïve patients
(n = 104) or patients with prior null response to PegIFN and
RBV (n = 43), including patients with cirrhosis [37]. Patients were
randomized to treatment with DCV/SMV either with or without
RBV for 12 weeks. At week 12, patients were re-randomized to
stop treatment or to continue therapy for another 12 weeks. A
small cohort of HCV genotype 1a-infected patients (n = 12 ther-
apy naïve and n = 9 null-responder to previous PegIFN and RBV)
were treated with both DAAs plus RBV for 24 weeks. Response
rates were 75–85% and 65–95% in HCV GT1b treatment-naïve
and prior null-responders with HCV genotype 1 infection, respec-
tively. For HCV GT1a-infected treatment-naïve patients, SVR12
rates were reported with 67%. GT1a null-responders were offered
rescue therapy with addition of PegIFN after ﬁve patients experi-
enced viral breakthrough.
The 24-week combination of simeprevir (150 mg) and a
higher dose of daclatasvir (60 mg), and RBV is currently investi-
gated in HCV GT1b-infected patients with recurrent HCV
infection after orthotopic liver transplantation, results are not
yet available [38].Simeprevir and samatasvir + RBV
The HELIX-1 study investigated the oral combination of simepre-
vir (150 mg) and samatasvir (25, 50, 100, and 150 mg), a secondJournal of Hepatology 201generation NS5A inhibitor, in treatment-naïve, non-cirrhotic HCV
genotype 1b- or 4-infected patients [39]. SVR4 rates were 47–80%
for HCV GT1b patients (n = 84) and 100% for HCV GT4 patients
(n = 9).Combination of the second generation NS3/4A inhibitor MK-5172
and MK-8742 ± RBV
Recently, results were also presented from the phase 2 C-WOR-
THY trial [40–42]. This study, a two-part, parallel-group, random-
ized (within group) clinical trial, investigated the all-oral,
interferon-free, once daily, ﬁxed dose combination of the second
generation NS3/4A protease inhibitor MK-5172 and MK-8742, a
NS5A replication complex inhibitor. Overall, the study included
471 HCV genotype 1 patients that were enrolled across 16 arms.
C-WORTHY, part A, included 65 HCV treatment-naïve genotype 1
patients without cirrhosis who received MK-5172 (100 mg QD)
and MK-8742 (20 or 50 mg QD), with or without RBV for
12 weeks. All HCV GT1a-infected patients were randomized to
RBV containing arms. SVR12 rates, as reported at AASLD 2013,
were 89–100%. In HCV genotype 1b patients the presence or
absence of RBV did not impact SVR rates [40].
Treatment with MK-5172/MK-8742 (50 mg QD) ± RBV was
expanded to several groups. These included (1) treatment-naïve,
non-cirrhotic patients (C-WORTHY, part B), investigating the dual
DAA combination with or without RBV for 8 or 12 weeks; (2)
treatment-naïve cirrhotic patients (n = 123); and (3) non-cir-
rhotic and cirrhotic null-responders to previous therapy with
PegIFN and RBV (n = 130). Groups (2) and (3) received 12 or
18 weeks of MK-5172/MK-8742 either with or without RBV.
Results of the combined analysis of C-WORTHY part A and
part B were presented at EASL 2014. SVR8 rates, available for
93% of the patients who received MK-5172/MK-8742 and RBV
for 8 weeks, were 83%. SVR24 results were available for 100% of
the patients who were enrolled into part A, SVR8 data for 93%
of the part B participants. Combined response rates were 94%
and 98% for a twelve week treatment with MK-5172/MK-8742
with and without RBV, respectively. Also, SVR4/8 rates were
reported with 90–97% and 91–100% for (1) and (2), respectively
[41,42].
The oral combination of MK-5172 and MK-8742 was generally
safe and well tolerated. Common AEs (P10%) reported in differ-
ent study arms comprised fatigue, headache, nausea, diarrhoea,
asthenia, and insomnia. Anaemia was not reported in the RBV4 vol. 61 j S98–S107 S101
Treatment
Table 2. Summary of selected clinical trials investigating the combination of a NS3/4A protease inhibitor and a NS5A inhibitor ± RBV.
Sponsor Trial name
or NCT ID
Phase DAA combination RBV Patient population Treatment
(wk)
Outcome 
(SVR)
AbbVie AVIATOR 2 ABT-450/r + ombitasvir + RBV HCV GT1, therapy naïve and experienced (prior null- 
responders), no cirrhosis
12 Naïve: 89%
Null-responders: 89%
PEARL-I 2 ABT-450/r + ombitasvir
Ø RBV
± RBV
Substudy 1
HCV GT1b, naïve, prior null-responders, no cirrhosis
HCV GT4, naïve, experienced (prior partial-/null- 
responder, relapser), no cirrhosis
Substudy 2
HCV GT1b, naïve, experienced, cirrhosis
12
12
24
Naïve: 95.2 %, null-responders: 90%
Naïve: 100% (+RBV), 91% (Ø RBV)
Experienced: SVR12 not yet available
Ongoing
NCT02068222 2 ABT-450/r + ABT-530 ± RBV HCV GT3, naïve, no cirrhosis 12 Ongoing
Achillion NCT01849562 2 Sovaprevir + ACH-3102 + RBV HCV GT1, naïve, no cirrhosis 12 Naïve, GT1b 100%
Bristol-Myers-
Squibb
NCT01012895 2 Asunaprevir + daclatasvir Ø RBV HCV GT1, prior null-responders, no cirrhosis 24 GT1a: 22%
GT1b: 100%
NCT01051414 2 Asunaprevir + daclatasvir 
(Japan)
Ø RBV HCV GT1b, prior null responder; PegIFN intolerant/
ineligible, no cirrhosis
24 Null-responders: 90.5%
Ineligible/intolerant: 63.6%
NCT01012895 2 Asunaprevir + daclatasvir 
(US)
± RBV HCV GT1, prior null-responder, no cirrhosis 24 60-83% (GT1b)
NCT01497834 3 Asunaprevir + daclatasvir 
(Japan)
Ø RBV HCV GT1b, PegIFN intolerant/ineligible, prior null-/
partial responder ± cirrhosis
24 Ineligible/intolerant: 87.4%
Null/partial responder 80.5%
Hallmark-Dual 3 Asunaprevir + daclatasvir Ø RBV HCV GT1b, naïve, PegIFN  intolerant/ineligible, prior 
null-/partial responder, ± cirrhosis
24 Naïve: 90%
Ineligible/intolerant: 82%
Null/partial responder: 82%
Bristol-Myers-
Squibb/Janssen
LEAQUE-1 2 Simeprevir + daclatasvir ± RBV HCV GT1, naïve, prior null-responder, no cirrhosis 12, 24 Naïve, GT1b: 75-85%
Null-responder, GT1b: 65-95%
Naïve, GT1a: 67%
NCT01938625 2 Simeprevir + daclatasvir + RBV HCV GT1b, recurrent chronic HCV infection after 
orthotopic liver transplantation
24 Ongoing
Janssen/Merck HELIX-1 1,4 Simeprevir + samatasvir + RBV HCV GT1b, 4, naïve, no cirrhosis 12 GT1b 47-80%
GT4: 100%
Merck C-WORTHY 2 MK-5172/MK-8742 ± RBV
± RBV
HCV GT1, naïve, no cirrhosis (Part A)
expansion cohorts: naïve, ± cirrhosis; 
null responders ± cirrhosis
12 Naïve, no cirrhosis: 89-100% (Part A) 
Expansion groups ongoing
C-SCAPE 2 MK-5172/MK-8742 ± RBV HCV GT2, 4-6, treatment-naïve, no cirrhosis 12 Ongoing
C-SALVAGE 2 MK-5172/MK-8742 + RBV HCV GT1 treatment-experienced (incl. DAA failure) 
± cirrhosis
12 Ongoing
C-EDGE TN 3 MK-5172 + MK-8742 Ø RBV HCV GT1, 4-6, naïve, ± cirrhosis 12 Ongoing
C-EDGE TE 3 MK-5172 + MK-8742 ± RBV HCV GT1, 4-6, experienced (incl. DAA failure) 
± cirrhosis
12, 16
8, 12; 12, 18
Ongoing
NCT02115321 2/3
2
MK-5172 + MK-8742 Ø RBV HCV GT1, 4-6, naïve, CHILD B cirrhosis 12 Ongoing
NCT01932762 MK-5172 + MK-8742 ± RBV GT 2, 4, 5, and 6, naïve, no cirrhosis 12 Ongoing
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Table 3. Summary of selected clinical trials investigating the combination of a NS3/4A protease inhibitor and a non-nucleoside polymerase inhibitor ± RBV.
Sponsor Trial name
or NCT ID
Phase DAA combination RBV Patient population Treatment
(wk)
Outcome (SVR)
AbbVie AVIATOR 2 ABT-450/r + dasabuvir + RBV HCV GT1, naïve, no 
cirrhosis
12 Naïve: 83%
CO-PILOT 2 ABT-450/r + dasabuvir + RBV HCV GT1, naïve, prior null 
or partial responder, 
no cirrhosis
12 Naïve: 79-89%
Experienced: 47%
PILOT 2 ABT-450/r + ABT-072 + RBV HCV GT1, IL28B CC, naïve, 
no cirrhosis
12 Naïve: 91%
JOURNAL OF HEPATOLOGYfree-arms. The numbers of discontinuations, due to laboratory
abnormalities, AEs and SAEs were generally low (63% in study
arms that included patients with cirrhosis, respectively).
The results of additional phase 2 trials, involving the combina-
tion MK-5172/MK-8742 ± RBV, are pending, the phase 3 study
program has just started (Table 2).
Ongoing or planned trial activities also include assessment of
this DAA combination in patients with Child-Pugh-B cirrhosis and
HCV GT2- and 3-infected patients [43,44].T
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polymerase inhibitor ± RBV
Several trials investigated the combination of a NS3/4A protease
inhibitor, a non-nucleoside polymerase inhibitor with or without
RBV (Table 3).ABT-450/r and dasabuvir (ABT-333) + RBV
The combination of the NS3/4A protease inhibitor ABT-450/r, the
non-nucleoside polymerase inhibitor dasabuvir and RBV was
investigated in the phase 2 AVIATOR and CO-PILOT study
[27,45]. In the AVIATOR study (outlined above) response rates
for 41 treatment-naïve patients without cirrhosis treated with
ABT-450/r (150/100 mg QD), dasabuvir (400 mg BID) and RBV
for 12 weeks were 83% [27]. The CO-PILOT study tested
ABT450/r (250 mg/100 mg or 150 mg/100 mg) in combination
with dasabuvir (400 mg BID) and RBV for 12 weeks in non-
cirrhotic treatment-naïve HCV genotype 1 patients (group 1:
n = 19 and group 2: n = 14 patients) and patients with prior
partial or null response to PegIFN and RBV (group 3: n = 17)
[45]. Reported SVR rates were 89%, 79%, and 47% in groups 1, 2,
and 3, respectively.ABT-450/r and ABT-072 + RBV
The PILOT study investigated a 12 week oral combination treat-
ment of ABT-450/r (150/100 mg QD) and the non-nucleoside
polymerase inhibitor ABT-072 (400 mg QD) and RBV in 11 treat-
ment-naïve, non-cirrhotic HCV genotype 1 patients with the
IL28B-CC genotype [46]. 10 patients (91%) had a SVR24. One
patient relapsed 36 weeks after the end of treatment. At the time
of relapse, a NS5B resistance variant (Y448H), that was not pres-
ent in the baseline sample, was detected. Clinical development of
ABT-072 is currently not further pursued.
Currently, non-nucleosidic polymerase inhibitors are further
considered as components in multiclass DAA combination trials.Journal of Hepatology 201Triple DAA combinations (a NS3/4A protease inhibitor, a NS5A
inhibitor and a non-nucleoside polymerase inhibitor) ± RBV
ABT-450/r, ombitasvir and dasabuvir ± RBV
Successful therapy with the triple DAA (‘‘3D’’) combination of
ABT-450/r, ombitasvir and dasabuvir was ﬁrst reported from
the AVIATOR study (outlined above). SVR rates were 88–96%
and 93–95% in treatment-naïve patients and patients with prior
null response to PegIFN/RBV, respectively. SVR rates were lower
in the RBV-free and the 8 week treatment arms. RBV dose reduc-
tions, however, did not signiﬁcantly impact SVR rates. Also, base-
line resistance variants did not impact treatment outcomes in
HCV GT1a- and HCV GT1b-infected patients treated with 3 DAAs.
One single HCV GT1b patient, who did not achieve SVR, did not
have baseline resistance-associated variants in NS3, NS5A, or
NS5B [47].
Results of the respective phase 3 program, comprising the
studies SAPPHIRE-I, SAPPHIRE-II, TURQUOISE-II and PEARL-IV,
PEARL-III, and PEARL-II were reported recently [48–52] (Table 4).
The placebo-controlled SAPPHIRE-I and SAPPHIRE-II trials
investigated ABT-450/r–ombitasvir (150/100 mg–25 mg QD,
available as single-tablet formulation) and dasabuvir (250 mg
BID) with RBV for 12 weeks in treatment-naïve and experienced
HCV genotype 1-infected patients without cirrhosis [48,49].
Overall, SVR rates were 96.2% and 96.3%, respectively (Table 4).
SVR rates were high across subgroups (HCV GT1a and GT1b) as
well as independent of prior treatment status. In both studies,
rates of virologic failure were low. In SAPPHIRE-I, viral break-
through or relapse occurred in 0.2% and 1.5% of the patients,
respectively. All of the eight patients with virologic failure had
one or more resistance associated variant(s) at the time of break-
through or relapse. In SAPPHIRE-II, no virologic failure occurred
during treatment. Seven patients had a viral relapse post treat-
ment. Of those, ﬁve had at least one resistance-associated variant
at the time of relapse. In both studies treatment was well toler-
ated, and treatment discontinuations due to adverse events were
low (0.6% in SAPPHIRE-I, and 1% in SAPPHIRE-2). In SAPPHIRE-1,
grade 1 or 2 haemoglobin reductions occurred in 47.5% and 5.8%
of the patients, respectively. Haemoglobin levels of grade 2 and 3
were observed in 4.7% and 0.3% of the SAPPHIRE-II participants,
respectively. Grade 3 or 4 hyperbilirubinaemia (SAPPHIRE-I:
2.4%, SAPPHIRE-II: 2.8%) was mostly transient and attributable
to elevation of indirect bilirubin. None of these liver enzyme
elevations met Hy’s law criteria.
The open-label TURQUOISE-II trial enrolled previously
untreated and previously treated patients with compensated
liver cirrhosis and randomized these patients to 12 vs. 24 weeks4 vol. 61 j S98–S107 S103
Treatment
Table 4. Summary of selected clinical trials investigating triple DAA combinations (a NS3/4A protease inhibitor, a NS5A inhibitor and a non-nucleoside polymerase inhibitor) ± RBV.
Sponsor Trial name
or NCT ID
Phase DAA combination RBV Study population Treatment
(wk)
Outcome
(SVR)
AbbVie AVIATOR 2 ABT-450/r + ombitasvir + dasabuvir ± RBV HCV GT1, naïve, prior null-responder, no 
cirrhosis
8, 12, 24 Naïve: 88-96%
Null-responder: 93-95%
SAPPHIRE-I 3 ABT-450/r–ombitasvir + dasabuvir + RBV HCV GT1, naïve, no cirrhosis 12 Naive 96.2%
SAPPHIRE-II 3 ABT-450/r–ombitasvir + dasabuvir + RBV HCV GT1, therapy experienced (relapse, 
partial-/null-responder), no cirrhosis
12 Experienced: 96.3%
TURQUOISE-II 3 ABT-450/r–ombitasvir + dasabuvir + RBV HCV GT1, naïve, experienced (relapse, 
partial-/null-responder), cirrhosis
12, 24 Overall: 91.8-95.9%
PEARL-IV 3 ABT-450/r–ombitasvir + dasabuvir ± RBV HCV GT1a, naïve, no cirrhosis 12 Naïve GT1 a 97.0 % (+ RBV); 
90.2% (- RBV)
PEARL-III 3 ABT-450/r–ombitasvir + dasabuvir ± RBV HCV GT1b, naïve, no cirrhosis 12 Naïve, GT1b ~ 99.0%
PEARL-II 3 ABT-450/r–ombitasvir + dasabuvir ± RBV HCV GT1b, therapy experienced, no 
cirrhosis
12 Naïve GT1b, 97.0 % (+ RBV); 
100% (- RBV)
M12-999 2 ABT-450/r–ombitasvir + dasabuvir + RBV HCV GT1, liver transplant recipients with 
recurrent infection
23 96.2%
Bristol-Myers-
Squibb
NCT01455090 2 Asunaprevir + daclatasvir + BMS-791325 Ø RBV HCV GT1, 4, naïve, ± cirrhosis 12, 24 Naïve, GT1 92% (70%, cirrhosis)
Naïve, GT4: 100%
UNITY 1 3 Asunaprevir + daclatasvir + BMS-791325 Ø RBV HCV GT1, therapy naïve, no cirrhosis 12 Ongoing
UNITY 2 3 Asunaprevir + daclatasvir + BMS-791325 Ø RBV HCV GT1, therapy naïve, cirrhosis 12 Ongoing
UNITY 3
(Japan)
3 Asunaprevir + daclatasvir + BMS-791325 Ø RBV HCV GT1, therapy naïve ± cirrhosis 12 Ongoing
Janssen/
GlaxoSmithKline
NCT01724086 2 Simeprivir, GSK2336805, TMC647055 
plus low-dose ritonavir
± RBV HCV GT1, therapy experienced, no cirrhosis 12 Planned
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of therapy (n = 208 and n = 172) with the above DAA combination
(‘‘3D’’) plus RBV [50]. Overall SVR rates were 91.8% (12 weeks)
and 95.9% (24 weeks). SVR rates for HCV genotype 1 infected
patients with prior null response were 80.0% (95% CI:
68.9–91.1) and 92.9% (95% CI: 85.1–100) for 12 and 24 weeks
of treatment, respectively.
Virologic failure during treatment occurred in 0.5% of the
patients in the 12-week group and in 1.7% of the patients in the
24-week group. Signiﬁcantly less patients in the 24-week group
than in the 12-week group had a relapse after treatment (0.6%
vs. 5.9%). Seven of twelve patients (58.3%) who relapsed after
12 weeks of treatment had a HCV genotype 1a infection and a
prior null response to treatment with PegIFN and RBV. Most
patients had resistance associated variants at the time of viro-
logic failure. Treatment was discontinued due to AEs in 2% of
the patients. Grade 1 or 2 reductions in haemoglobin levels were
common (grade 1 52.6%, grade 2 7.9%). Grade 3 and 4 haemoglo-
bin abnormalities, however, occurred in only 0.8% and 0.3% of the
patients, respectively. Grade 3 or 4 bilirubin elevations that
mainly reﬂected elevations of indirect bilirubin were observed
in 9.7% of the patients. There were no concomitant grade 3 or 4
aminotransferase abnormalities.
In the ‘‘3D’’ regimen, common adverse events were generally
mild and, across the program, included e.g. pruritus, nausea,
headache, diarrhoea, insomnia, and asthenia. In patients with
cirrhosis, the safety and efﬁcacy was similar compared to studies
in non-cirrhotic patients.
The impact of addition of RBV to the ‘‘3D’’ combination was
investigated in the PEARL-IV and PEARL-III studies that enrolled
treatment-naïve HCV genotype 1a and HCV genotype 1b patients
without cirrhosis, respectively [51]. Concomitant treatment with
RBV was associated with higher response rates in HCV
GT1a-infected patients (SVR [3D + RBV, n = 100]: 97.0% [95% CI:
93.7–100]; SVR [3D, n = 205]: 90.2% [95% CI: 86.2–94.3]) but
not in patients with HCV genotype 1b infection (SVR [3D + RBV,
n = 210]: 99.5%; SVR [3D, n = 209]: 99%).
The PEARL-II study included treatment-experienced patients
with HCV genotype 1b infection who received 3D with and with-
out RBV (n = 88 and n = 91 patients) [52]. Sustained virologic
response rates were 97% and 100%, respectively.
Results of a phase 2 study that investigated the 3D regimen
plus RBV in adult liver transplant recipients with recurrent HCV
GT1 infection reported a SVR12 rate of 96.2% in this population
[53] No rejection, graft losses, or death was observed.
Asunaprevir, daclatasvir and BMS-791325
The interferon- and RBV free combination of asunaprevir (200 mg
BID) and daclatasvir (60 mg QD) was investigated in combination
with the non-nucleoside NS5B inhibitor BMS-791325 (75 or
150 mg BID) for 12 or 24 weeks in 66 treatment-naïve HCV geno-
type 1 infected patients without cirrhosis [54–56]. SVR12 rates
were 92% and did not differ signiﬁcantly by treatment duration
[54]. Expansion cohorts of this trial comprised a larger number
of previously untreated patients including those with liver cirrho-
sis, as well as HCV GT4 infected patients and patients who failed
prior therapy with PegIFN and RBV.
Results of the expansion cohort evaluating this triple DAA reg-
imen in a larger number (n = 166) of HCV genotype 1-infected
patients were presented at AASLD 2013 [55]. Patients were trea-
ted for 12 weeks with asunaprevir (200 mg BID), daclatasvirJournal of Hepatology 201(30 mg QD) and two different doses of BMS-791325 (‘325)
(150 mg and 75 mg BID). Overall observed SVR12 rates were sim-
ilar in the ‘325 150 mg and 75 mg groups (91.7% and 92.2%,
respectively). In patients with liver cirrhosis 8/8 patients (100%)
who received the ‘325 75 mg dose had a SVR, compared to 5/7
(70%) who received the 150 mg dose. SVR rates for n = 10 and
n = 11 HCV genotype 4 patients who were treated for 12 weeks
with this triple DAA combination and the two different BMS-
701325 doses were 100% [56]. Results for treatment-experienced
HCV genotype 1 patients are not yet available. Reported adverse
events that occurred with a frequency of P10% comprised head-
ache, asthenia, diarrhoea, and fatigue. Grade 3/4 laboratory
abnormalities were reported in 6.3% and 1.3% percent for the
pilot and extension cohorts, respectively. The phase 3 program,
applying a twice-daily combination of daclatasvir, asunaprevir,
and BMS-791325 (75 mg) is underway [57–59].Simeprevir, GSK2336805 and TMC647055/r ± RBV
A pharmaceutical cross-collaboration investigating the NS3/4A
protease inhibitor simeprevir in combination with the non-
nucleoside polymerase inhibitor TMC647055 plus low-dose
ritonavir with and without RBV and simeprevir plus
TMC647055/r administered together with GSK2336805 without
RBV is currently planned [60].Host-targeting agents
In parallel to the development of DAAs, host factors associated
with viral entry and replication were identiﬁed as drug targets.
Up to now, two HTAs entered phase 2/3 clinical trials, the cyclo-
philin A inhibitor alisporivir, and miR-122 antagonist Miravirsen.
Cyclophilin A, a cellular enzyme with isomerase and chaper-
one activity, governs HCV replication and assembly via interac-
tion with HCV NS5A and NS5B proteins. Alisporivir mediates its
antiviral activity by directly binding to the enzymatic pocket of
cyclophilin A. As cyclophilin A is relevant for HCV replication
across genotypes and since it does not directly interact with viral
proteins, alisporivir provides pan-genotypic activity and high
barrier to resistance [61–63]. In 2012 the development program
of alisporivir was set on hold due to safety concerns emerging
from six severe cases of pancreatitis, including one death in the
alisporivir/PegIFN combination trials. After extensive safety anal-
yses, the interferon-free alisporivir development program was
resumed. Currently, a phase 2 trial investigates response-guided
therapy with alisporivir plus RBV for 12–24 weeks in treatment-
naïve, HCV genotype 2/3-infected patients, however, results are
not yet available.
The liver-speciﬁcmicro-RNAmiR-122 assures efﬁcient replica-
tion of HCV-RNA, presumably by binding to HCV 50-UTR, and thus
protecting the viral RNA against cellular nucleases [64]. A recent
phase 2 study tested the efﬁcacy of the miR-122 antagonist
miravirsen against placebo. Results showed a dose-dependent
reductionofHCV-RNAof up to 3 log10 IU per ml [65]. Given its only
moderate antiviral effect in monotherapy, miravirsen still has to
prove its potential in combination therapies. A phase 2 study that
investigates the efﬁcacy of miravirsen in combination with tela-
previr and RBV in null-responders to prior therapy with PegIFN
and RBV was initiated recently [66].4 vol. 61 j S98–S107 S105
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Summary
Laborious molecular research led to the characterization of the
HCV life cycle and opened the gates for turbulent and eventful
years in clinical drug development. TheNS3/4Aprotease inhibitors
telaprevir and boceprevir made the start, but were outpaced only
two years after their approval by the availability of the nucleotide
polymerase inhibitor sofosbuvir, offering the ﬁrst interferon-free
therapeutic option. Sustained virologic response rates, achieved
with all-oral combination therapies, involving sofosbuvir in com-
bination with a NS3/4A inhibitor or a NS5A inhibitor, certainly
raise the bar but are challenged by competitive and also nearby
available all-oral DAA combination therapies without a nucleotide
polymerase inhibitors, as summarized herein. Also, the very good
tolerability of the novel interferon-free DAA combination thera-
pies now put the spotlight on RBV as undesirable combination
partner. Also, it enables to progressively move clinical testing to
previously difﬁcult-to-cure populations, such as patients with
decompensated liver cirrhosis, transplant-recipients and patients
with end-stage renal disease. The development of ﬁxed-dose for-
mulations, reduced drug-drug interactions and shortened therapy
durations (8–12 weeks) further facilitate the clinical applicability
of the novel DAA regimens. With ‘‘perfect certainly not being the
enemy of good’’ in today’s race towards all-oral interferon-free
DAA combination therapies, trials investigating 4-week combina-
tion therapies are underway [67]. However, the dream of widely-
available antiviral HCV treatments is challenged by the reality of
high costs, urgently requiring medical experts, pharmaceutical
industry and health care policy makers to deﬁne the framework
for the routine use of novel DAA combinations in clinical practice.Conﬂict of interest
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